Abstract. Matching the bolus arrival time (BAT) of the arterial input function (AIF) and tissue residue function (TRF) is necessary for accurate pharmacokinetic (PK) modeling of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). We investigated the sensitivity of volume transfer constant (K trans ) and extravascular extracellular volume fraction (v e ) to BAT and compared the results of four automatic BAT measurement methods in characterization of prostate and breast cancers. Variation in delay between AIF and TRF resulted in a monotonous change trend of K trans and v e values. The results of automatic BAT estimators for clinical data were all comparable except for one BAT estimation method. Our results indicate that inaccuracies in BAT measurement can lead to variability among DCE-MRI PK model parameters, diminish the quality of model fit, and produce fewer valid voxels in a region of interest. Although the selection of the BAT method did not affect the direction of change in the treatment assessment cohort, we suggest that BAT measurement methods must be used consistently in the course of longitudinal studies to control measurement variability.
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Introduction
Microvasculature characteristics of the cancerous tissues, such as vascular permeability, cellularity, and metabolism, are actively being investigated as potential biomarkers for monitoring cancer progression and evaluating treatment response, especially in tumor tissues with rapid angiogenesis [1] [2] [3] [4] primarily because of the earlier response time of these biomarkers to the treatment compared with that of the more routine standard of care metrics, such as monitoring tumor size changes. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a minimally invasive imaging technique based on the hemodynamic response of the tissue to the intravenous injection of contrast agent (CA) that has the potential for microvasculature characterization of normal and cancerous tissues. 5 Pharmacokinetic (PK) compartmental models, such as Tofts model (TM), are widely used for DCE-MRI data analysis to extract quantitative parameters relating to the tissue hemodynamics and vasculature, such as volume transfer constant (K trans ) and the extravascular extracellular space (EES) fraction (v e ). 6, 7 One of the challenges in reliable and reproducible quantification from DCE-MRI is its well-recognized dependence on the acquisition and analysis approaches. 8 Although the true microvasculature characteristics are independent of the imaging conditions (e.g., MRI scanner platform, data acquisition details, bolus dose), several studies suggest that accuracy and reproducibility of PK parameters are sensitive to the processing techniques. [8] [9] [10] [11] [12] [13] The knowledge of CA concentration uptake in the arterial input function (AIF) is required in order to fit the PK mathematical models to the tissue residual function (TRF). The process of PK fitting requires bolus flight time delay correction, i.e., aligning the bolus arrival time (BAT) of the AIF and TRF curves. It was demonstrated that the error in estimation of the delay between AIF and TRF can have a large effect on the accuracy of parameter estimation. 14, 15 With the exception of the methods that are not sensitive to the bolus arrival delay, 16, 17 correction for such a delay is otherwise necessary. 18 This correction can be done by adding the delay as a free parameter to the PK analysis optimization procedure at the expense of making the fitting process more complex. 19, 20 There is evidence that PK models that have fewer parameters result in improved robustness and stability of the fit 21 and that exclusion of BAT from the fitting problem reduces the model's degrees of freedom and improves the accuracy of the estimates and the stability of the model. 22 Alternatively, delay correction can be performed directly as a step preceding the PK analysis. In this paper, we focus on the latter class of optimization approaches where the delay correction is done prior to the PK modeling.
Such approaches are commonly used in the quantitative analysis of DCE-MRI, as evident from numerous publications. Nevertheless, while direct optimization approaches are commonly used and it is well known based on simulations that accurate delay correction is critical for the accurate analysis, the effects of errors in delay correction have not been investigated in clinical data or digital phantoms.
Performed outside the optimization procedure, delay correction relies on the measurement of the BAT in AIF and TRF. Bolus delay correction can be performed manually by visually identifying the arrival of bolus, but in practice, this is feasible only for ROI-based analysis and may affect repeatability of the analysis. BAT measurement has been studied extensively in hemodynamic characterization of vessels, 23, 24 but less so in a DCE-MRI PK modeling field. It should be noted that detection of BAT in TRF signals is more challenging than in arteries (e.g., AIF) due to the differences in the uptake profiles that depend on tissue properties and, in some cases, broad concentration time curves with slight slopes in washout time regions following onset of the enhancement. Several approaches for automatic estimation of BAT have been proposed. [25] [26] [27] [28] [29] Huisman et al. 25 developed a three-component model for prostate with BAT as a parameter estimated by fitting a curve that focuses on the most probable slope. In Ref. 26 , BAT TRF was calculated using the concentration time curve of the entire region of interest (ROI) and measuring the BAT from the intersection of the lines joining a predetermined number of adjacent points and then using the same BAT for all of the voxels within the same ROI. Automatic detection of BAT, based on fitting piecewise linear functions to the concentration curve, has been proposed by Cheong et al. 27 with a two-segment linear model and by Singh et al. 29 with a three-piece linear model. Studies have shown that inaccurate estimation of BAT can lead to uncertainty in the PK estimates. 20, 30 Although the importance of accurate compensation for BAT has been recognized, there has not, to the best of our knowledge, been a systematic investigation of the sensitivity of the PK modeling to this parameter, or comparison of BAT estimation approaches in characterization of tissue microvasculature. In this study, we do not aim to introduce or improve approaches to BAT estimation or delay correction. Instead, we quantify the effects of variations in AIF delay correction on PK parameters and compare four previously published approaches for automatic estimation of BAT in DCE-MRI data: two regression-based piecewise linear modeling methods and two heuristic gradient-based methods. We investigated the effect of BAT on K trans and v e and the R 2 quality of fit in TM. The experiments were conducted on both synthetic and clinical DCE-MRI data. The patient images were collected in men with diagnosed prostate cancer (PCa) and in women with diagnosed breast cancer (BCa). The DCE-MRI analysis software tools used in this study are open-source and publicly available for use by other groups and for facilitating reproducibility of our results.
Materials and Methods
The evaluation consisted of two main components. First, we investigated the sensitivity of the estimated TM parameters to the delay between AIF and TRF. Then we applied four automatic approaches for BAT estimation on clinical DCE-MRI images to evaluate their consistency and compared the model parameters and quality of the fit that resulted from each of the methods. Experiments were conducted on a DCE-MRI digital reference object (DRO) and on the clinical datasets obtained for PCa and BCa patients.
Dynamic Contrast-Enhanced Magnetic
Resonance Imaging Data Fig. 1 . Each pixel contains the signal intensity of the time course data generated using TM sampled with a 4 s temporal resolution, with a patch of 10 × 10 pixels for each combination of K trans and v e parameters of TM. As illustrated in Fig. 1 , and 0.5). The DRO was created using the following parameters: flip angle 30 deg, repetition time ðTRÞ ¼ 5 ms, the native (precontrast) value of T 1 (T 10 ) was assumed to be 1000 ms in tissue and 1440 ms in blood. The DRO simulates image acquisition for 360 s with the injection of bolus occurring after 1 min. For MR modeling of the contrast uptake, blood hematocrit was assumed to be 45% and the relaxivity of the gadolinium CA at 1.5 T was assumed to be 0.0045 mmol −1 ms −1 . 32 The AIF ROI was included as a separate image patch in the same image volume.
Prostate cancer
PCa MRI images were acquired through a HIPAA compliant study that was approved by the Institutional Review Board (IRB) at Brigham and Women's Hospital, Boston, Massachusetts. Informed written consent was obtained from the patients participating in the study. MRI data of a total of nine patients with histologically confirmed PCa were collected and analyzed. MR images were acquired on a GE Signa HDx 3.0 T magnet (GE Healthcare, Waukesha, Wisconsin) using a combination of an eight-channel abdominal array and endorectal coil (Medrad, Pittsburgh, Pennsylvania). A set of multiparametric MR sequences, including T 1 -and T 2 -weighted imaging, diffusion weighted imaging, and DCE-MRI was performed for each patient. 33 The datasets were previously released in Ref. 13 and are available, by request, from the Quantitative Imaging Network QIN-PROSTATE collection 13, 34 of The Cancer Imaging Archive (TCIA) 35 in Digital Imaging and Communications in Medicine (DICOM) format.
DCE-MRI images were acquired with a three-dimensional (3-D) spoiled gradient recalled (SPGR) sequence with TR∕ TE∕α ¼ 3.6 ms∕1.3 ms∕15 deg, FOV ¼ 26 cm 2 , covering the full gland with an image voxel size of 1 × 1 × 6 mm 3 . Temporal resolution for acquiring DCE MRI frames was ∼5 s. Gadopentetate dimeglumine (Magnevist, Berlex Laboratories, Wayne, New Jersey) CA was injected intravenously using a syringe pump (0.15 mmol∕kg) at the rate of 3 ml∕s followed by 20 ml saline flush at the same rate. Imaging protocol included five baseline scans prior to the bolus injection. T 1 -weighted images were acquired with an SPGR echo sequence with TR∕TE∕α ¼ 385 ms∕6.2 ms∕65 deg over a 16-cm 2 field of view (FOV). An abdominal radiologist with more than 10 years of experience interpreting prostate MRIs used the free and open-source software platform 3D Slicer software 36 to contour tumor region of interest (TROI) localization. ROI contouring was aided by the pathology report of the prostatectomy and/ or biopsy specimen and concomitant MR findings for PCa. The AIF curve was acquired by contouring an ROI from the left femoral artery and averaging the concentration curves for the ROI voxels. The prostate gland was segmented manually on each slice of each image volume.
Breast cancer
Breast DCE-MRI data were acquired on patients (N ¼ 10) with locally advanced breast cancer, who received preoperative neoadjuvant chemotherapy (NACT) in an IRB approved, HIPPA compliant study at Oregon Health and Science University (OHSU), one of the QIN centers. DCE-MRI images were collected at the pre-NACT first visit (V1) and following the first cycle of the NACT second visit (V2). Breast MR images were acquired using a Siemens 3T system with a body coil transmitter and a four-channel bilateral phased array breast coil receiver. DCE-MRI acquisition parameters included 10-deg flip angle, 2.9∕6.2 ms echo time/repetition time (TE/TR), a parallel imaging acceleration factor of two, 30 to 34 cm FOV, 320 × 320 inplane matrix size, and 1.4-mm slice thickness. According to Ref. 37 , the total acquisition time was ∼10 min for 32 to 34 image volume sets of 112 to 120 slices, each with 18-to 20-s temporal resolution. The time of injection of CA (HP-DO3A) [ProHance] IV (0.1 mmol∕kg at 2 ml∕s) was set to start following acquisition of two baseline image volumes using a programmable power injector and followed by a 20-ml saline flush. A population-averaged AIF was provided for all of the 20 datasets. The AIF was generated by averaging AIF measured in a population cohort that was imaged with the same CA injection protocol (dose, injection rate, and injection site-antecubital vein). 37 The OHSU MRI datasets were accompanied by the breast TROIs on post-CA multislice images covering the enhancing tumor component. The imaging data are available publicly in the TCIA QIN breast DCE-MRI collection. 38 TROIs, annotations, and parameters that are important for DCE analysis can be accessed from the QIN DCE-MRI analysis challenge website. 
Data Processing

Pharmacokinetic analysis
DCE-MRI images were processed using an inhouse prototype implementation of PK analysis software using Python 2.7 40 and SimpleITK. 41 The PK analysis tool is publicly available at the Quantitative Image Informatics for Cancer Research (QIICR) website. 42 PK modeling based on TM consists of two steps: (1) MR signal to concentration signal conversion and (2) fitting the concentration curve to the TM. T 1 can be measured from the spoiled gradient echo sequence [Eq. (1)] using the measured Signal S in presence of Gd, relaxed signal (S 0 ) and the MRI sequence parameters TR and flip angle (θ). According to the MR model, T 1 is reduced in the presence of the concentration agent, which can be modeled by Eq. (2), where T 10 is the T 1 of the tissue before CA injection, and r 1 is the CA relaxivity.
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TM models the flow of CA across the endothelium into the EES. In the second step, the concentration curve is fitted to the TM to find the model parameters transfer constant K trans , fractional volume of EES v e [Eqs. (3) and (4)]. We chose the twoparameter model without explicit plasma volume fraction term because of the instability in PK analysis and model fitting at the temporal resolution of the clinical data (>5 s): E Q -T A R G E T ; t e m p : i n t r a l i n k -; e 0 0 3 ; 6 3 ; 4 0 2 C t ðtÞ ¼ K trans
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where C b is the blood concentration, which can be determined from the blood signal using Eqs. (1) and (2). C p is the plasma concentration, which can be measured from C b and blood hematocrit (Hct). C t or TRF is the concentration of CA at the tissue. Different approaches can be used for constructing AIF, such as direct measurement from a feeding artery or population-averaged function. 43 Prior to modeling, delay correction must be applied at every voxel to match the CA arrival times of AIF and TRF. This requires measurement of BAT for AIF (BAT AIF ) and TRF (BAT TRF ). The discrete AIF signal is shifted in time to match BATs and compensate for the delay. Figure 2 illustrates the process of delay correction for a selected TRF voxel and an AIF. In this study, we only considered BATs aligned with the temporal sampling of the data which means we shifted signals in steps equal to the sampling time of the DCE-MRI acquisition (t s ).
The Levenberg-Marquardt least squares optimization algorithm was used 44 to fit the TRF concentration curves to the TM. We used the coefficient of determination, R 2 , as the measure for assessing the quality of model fits. A perfect fit would results in an R 2 value of 1. Given the dataset with n values ½y 1 ; : : : ; y i ; : : : ; y n , each corresponding to a modeled value of ½y 1 ; : : : ; y i ; : : : ; y n with mean y − , R 2 is defined as E Q -T A R G E T ; t e m p : i n t r a l i n k -; e 0 0 5 ; 3 2 6 ; 7 5 2
Automatic Bolus Arrival Time Estimation Methods
Our evaluation considered four approaches that operate on time courses of individual voxels of DCE-MRI images for automatic estimation of BAT. The first two methods use regression models to approximate the concentration time course with linear piecewise continuous functions. The linear-linear (LL) model proposed by Cheong et al. 27 approximates the curve with two linear components: baseline concentration and the contrast uptake region. The piecewise-linear (PL) model by Singh et al. 29 uses three linear components to approximate the baseline, uptake, and washout regions of the curve. In both methods, BAT is set as the point separating the first two linear components. The other two methods we considered are heuristics that attempt direct detection of BAT based on signal gradient changes. The first of these two methods is implemented in GE OncoQuant research software (GE Global Research, Niskayuna, New York) (further referred to as the OQ method); the second, the peak gradient (PG) method is available in the 3D Slicer PkModeling extension. 45 The regression-based methods, LL and PL, solve the least squares problem by iterating a range of timepoints and fitting the models to the concentration curves. The BAT is obtained from the fit that results in the smallest mean squared error. The LL model 27 is a two-piece linear model [Eq. (6)] in which β 0 is the precontrast concentration, β 1 is the slope of concentration curve during the bolus uptake, and ε½i is the error. BAT is estimated as the time t½k corresponding to the connecting point of the two straight lines. The search area for t½k in this method lies in the range of ½0; p in which p is the index of maximum value in the concentration time course array: E Q -T A R G E T ; t e m p : i n t r a l i n k -; e 0 0 6 ; 3 2 6 ; 3 3 2
The PL model 29 has two breaking points and is composed of three connecting straight lines [Eq. (7)]. The first separation point t½k is considered the BAT. Assuming that the number of points in the curve is n, in order to find the best fit, k is iterated from 0 to n − 2 and j is iterated from k to n − 1, and for each set of j and k, the best fit is calculated by minimization of the sum of squared errors. The values of k and j that make for the smallest sum of the squared errors are chosen as the optimum solution of curve fitting. The original method proposed by Singh et al. 29 uses a binary search method in the neighborhood of t½k to increase the precision of BAT estimation beyond the sampling interval. In this study, to be consistent with the other three methods, we only considered the integer values (BATs at sampling intervals):
E Q -T A R G E T ; t e m p : i n t r a l i n k -; e 0 0 7 ; 3 2 6 ; 1 2 7 The OQ method uses the gradient values of the signal, bolus concentration levels, and AIF information in determination of BAT. First, the concentration curve is transformed into the logarithmic domain so that BAT computation is more reliable due to noise suppression. Concentration values <0.001 mmol∕l are set to zero. Then the peak timepoint for either the AIF curve (if available) or the global curve (the cuve corresponding to the average of all voxels in the image volume) is measured. This time index becomes the starting point of the backward search for BAT for a given curve. If the prior estimate from the global curve or AIF is not available, then the entire curve is considered for searching to the method determines where the curve changes direction from steep descent to gradual flat roll-off from the point of backward search point. For this, the curve derivative is calculated allowing for determining the transition from high to low region (i.e., the kick-point of BAT). This is done by detecting the zero crossings of the curve differential so that both the roll up and roll down will give zero crossings in the derivative of the curve. By looking at the direction in which the crossing occurs, an upcrossing (desired target) and a down crossing are distinguished from one another. Finally, an upcrossing point closest to the initial guess point is used in a final BAT after accounting for index shift during the differentiation process.
Finally, the PG method finds BAT by measuring the point with the highest gradient and searching backward until the signal is DC plus noise.
Experimental Design
Sensitivity of pharmokinetic parameters to the arrival delay
Underestimation or overestimation of BAT AIF and BAT TRF leads to inaccuracies in delay correction. We hypothesize that these inaccuracies can potentially lead to variability in the estimated PK modeling parameters, including K trans and v e . To quantify such an effect, we designed simulations to investigate the effect of the delay between AIF and TRF on the estimation of PK parameters. These experiments utilized DCE-MRI image data of the DRO, and PCa and BCa patients' datasets. For DRO and PCa images, AIF was determined directly from the image and BAT AIF was manually assigned. In BCa data, population averaged AIF and BAT AIF were provided. For each image dataset, BAT AIF remained constant while BAT TRF was shifted around BAT AIF . Experiments were conducted by applying different delay times between AIF and TRF (BAT AIF − BAT TRF ) in the interval from −3t s to þ3t s in t s increments. Even though the negative delay (BAT TRF < BAT AIF ) is not physiologically possible, it was included in order to characterize the effect of BAT TRF underestimation or BAT AIF overestimation, which could occur in automatic estimation of BAT. For each of the seven experiments, PK parameters, K trans , v e , and goodness of fit R 2 were calculated. For DRO the percent errors relative to the ground truth were measured. It should be noted that the true value of the delay time is unknown for a given tissue since only integer shifts were considered if systematic errors as large as AEt s were present in the calculations.
Region of interest-based tissue characterization of patient data
In order to study the effect of BAT measurement choice and delay correction on the results of DCE-MRI tissue characterization with TM, we compared PK metrics acquired using four different approaches for BAT estimation: LL, PL, OQ, and PG, including ROI-based tissue characterization of 29 patient datasets (9 PCa patients and 10 BCa patients pre-and postNACT). For PCa DCE-MRI analysis, image-based patient specific AIFs were used. BAT AIF were determined automatically using the investigated BAT approaches applied to visual inspection of the patient specific AIF signal curves. In the BCa dataset, both models AIF and BAT AIF were supplied. Although the model AIF was population averaged, thus its BAT and number of points were defined based on the acquisition details for individual studies.
BAT TRF was estimated for every tissue voxel inside the delineated ROIs using the four automatic methods described above. Following the delay correction, TRF was fitted to the TM and K trans , v e , and R 2 goodness of fit were measured four times with differently measured BAT TRF estimates. To ensure using only the acceptable fit in ROI-based analyses and measurements, we considered well-fitted voxels as those with estimates that met the following criteria:
E Q -T A R G E T ; t e m p : i n t r a l i n k -; e 0 0 8 ; 6 3 ; 7 3 0
In Eq. (8), τ is the upper threshold for acceptable BAT values. The last criterion puts an acceptable bound on the measured BAT TRF to remove the tissue voxels with underestimated BAT TRF values (those that are less than BAT AIF , which is physiologically impossible) and discarding the overestimated outliers, which are lying outside the acceptable delay time.
Results
Results of ROI-based tissue characterization are presented separately for PCa and BCa patients in the following order: first, we evaluate the performance of each automatic BAT estimation method based on the percentage of voxels satisfying Eq. (8); next, we summarize the differences in the BAT measurements in the form of mean AE standard deviation for each patient study on the predefined ROIs; finally, we present the results of ROIbased tissue characterization in the form of PK parameters measured with different BAT estimators. For BCa patients, the effect of the BAT estimation approach on therapy response assessment is presented as K trans and v e percentage changes were measured for each BAT estimation approach. Percent changes of parameter P within the TROI between the two visits are defined as ðP V1 − P V2 Þ∕P V1 Ã 100.
Sensitivity of Pharmokinetic Parameters to the Arrival Delay
3.1.1 Digital reference object study Figure 3 shows the results of PK modeling with BAT AIF ¼ 60 s and different BAT TRF values for the three representative parameter combinations (pixel patches) of the DRO. We observed that delay between AIF and TRF leads to the deviation of K trans and v e from their true values, which is reflected as perturbations in the fitted curves relative to the curve corresponding to the ground truth parameter values. We observed that change in the approximate prescribed location of BAT TRF in either direction leads to increasing error in the estimated values of the PK parameters. Goodness of the model fit, as measured by R 2 , also diminishes with the deviation of the BAT TRF from the expected value that corresponds to the start of the contrast uptake at the phantom "tissue" pixels (see Fig. 4 ).
We conducted a set of tests similar to the phantom experiments, investigating the effect of delay between AIF and TRF on patient data PK modeling. Unlike in the phantom experiments, we could not evaluate percent error due to the lack of ground truth, but could observe general trends of change and the goodness of fit. Figures 5 and 6 illustrate the results of delay variations on PCa patient number #2 and BCa patient number #16 on visit 1, respectively. We observed that, consistent with the DRO experiments, there is a trend for monotonous increase/decrease of the values of K trans and v e , while the R 2 peaks at a patient specific timepoint. This pattern was also observed in the DRO sensitivity test (Fig. 4) . For PCa patient #2, R 2 boxplots have a peak mean showing the best goodness of fit at delay ¼ þ2t s (Fig. 5) . Figure 5 (a) shows that the visibly apparent uptake of the contrast in the tissue ROI occurs at approximately timepoint 9, which would require a delay correction of 2 time steps. The same pattern of change in K trans and v e due to BAT TRF deviation was observed in the BCa patient in Fig. 6 and the other PCa and BCa patients used in our analysis.
Region of Interest-Based Tissue
Characterization of Patient Data
Prostate cancer
For every DCE-MRI volume of the nine PCa patients, AIF was defined as the mean signal over the femoral artery ROI defined manually. The volumes of segmented regions (tumor and whole gland) for each patient case are shown in Table 1 . BAT AIF for each case was calculated using LL, PL, OQ, and PG methods. For all of the patients, there was agreement between the results of BAT AIF among all LL, PL, OQ, and PG methods except for three for patients: #10, #11, and #23 using OQ (Table 2 ). BAT TRF was measured for every voxel on the whole gland and TROIs using the four automatic methods under evaluation. TM was fitted to the TRF concentration curve and PK metrics were measured using the BAT TRF values estimated by each of the methods for every voxel inside the ROI. Valid voxels for tissue characterization were identified by determining those voxels that satisfy the constraints in Eq. (8) with τ ¼ BAT AIF þ 20t s . Percentage of the voxels satisfying the validity criteria for the tumor and the whole gland ROIs are summarized in Fig. 7 . On average, the use of individual BAT estimation methods resulted in the following mean AE standard deviation percentage of well-fitted voxels in the TROI: LL: 15.17 AE 17.66%, PL: 91.81 AE 9.69%, OQ: 97.96 AE 3.16%, PG: 95.54 AE 9.47%. For the whole gland, the numbers were lower: LL: 4.81 AE 4.33%, PL: 70.85 AE 6.82%, OQ: 79.20 AE 4.55%, PG: 64.67 AE 11.24%. In summary, there is a significant variability in the number of valid voxels in comparing different BAT approaches. The LL method appears to result in the largest number of failed voxels that either had unrealistic values of BAT or estimated PK parameters, or led to exceedingly poor model fits.
Different methods for the TROIs are summarized in Table 2 (the reported values are only for valid voxels). In summary, the variation in the estimated BAT TRF values appears to be rather small in relation to the temporal resolution of the acquisition (difference between means is less than 2 s). Figure 8 shows an illustrative example of the BAT TRF variability among different methods for PCa patient #11.
Finally, given the set of valid voxels for each of the BAT estimation approaches, we measured the effect of the BAT method on the estimated parameter values and the goodness of fit. Figure 9 shows the boxplots of K trans , v e , and R 2 for each of the patients over the valid voxels of the tumor and prostate whole gland ROIs with BAT TRF calculated by LL, PL, OQ, and PG methods. Except for the LL method, the results were rather consistent over the TROI. At the same time, significant heterogeneity in the estimated BAT values was observed when considering the whole gland.
Breast cancer
In BCa patients, AIF was prescribed as population averaged AIF; therefore, calculation of BAT AIF was not required. BAT TRF was measured using four automatic methods on the segmented TROIs for both visits of 10 BCa patients. The Table 1 The volumes of two sets of ROI delineated for prostate cancer patients' DCE-MRI datasets: tumor and whole prostate gland (N ¼ 9 volumes of segmented TROI for each patient in both visits are shown in Table 3 . Using the estimated BAT TRF of the four methods, TM fitting was performed on the TROIs of the DCE-MRI volumes and PK metrics were calculated for each visit. Since AIF was not patient specific, we could not use the BAT AIF as a lower bound to eliminate voxels with incorrect BAT TRF times [the last criterion of Eq. (8)]. However, according to the acquisition information, we knew that the first bolus injection occurred after taking two baseline images, so we chose the lower bound for valid BAT values as the second time point and the upper bound as the seventh time point: (2t s ≤ BAT TRF ≤ 7t s ). Figure 10 shows the percent of valid voxels identified using the modified constraints for both visits. On average, the use of individual BAT Table 4 .
Larger variability across the methods than that in the prostate dataset was observed. We also noted increased variability of the estimated BAT across voxels for a given method, especially for PG.
Again as with the PCa analysis, only valid voxels for each of the BAT estimation methods were included to measure K trans and v e values and the goodness of fit. Figure 11 depicts the boxplots of K trans , v e , and R 2 for each of the patients over the valid voxels for visit 1 and visit 2 TROIs using BAT TRF calculated by LL, PL, OQ, and PG methods. When we apply the validity constraints in Eq. (8) to the data, we observed relatively good agreement for K trans and v e (Fig. 11) . However, the selection of the BAT detection technique had a very strong effect on the number of voxels that met the validity constraints, as shown in Fig. 10 . For example, for visit 2 BCa patient #6, the percentage of valid voxels was %8.61, %35.46, %49.06, and %30.46 for LL, PL, OQ, and PG, respectively. K trans and v e percent changes between visit 1 and visit 2 were measured on valid voxels as a potential surrogate marker of tumor treatment response using different estimated BAT TRF values (Fig. 12) . Based on the tumor resection pathology reviews and pre-NACT biopsy specimens, patients #5, #6, and #15 achieved pathology-based complete response (pCR) following NACT. The remaining patients were non-pCR.
Discussion
It was our goal to investigate the effect of AIF delay correction and BAT measurement on PK parameters. To achieve this goal, we conducted phantom studies and evaluated the effect of the 1 and (b) visit 2 . Similar to the results observed for the prostate data, LL leads to the largest number of invalid voxels. However, the differences among the rest of the BAT methods considered were more prominent than those of the PCa dataset. underestimation of BAT TRF results in under-rating of K trans and over-rating of v e ; overestimation of BAT TRF results in over-rating of K trans and underrating of v e . This pattern was observed in DRO, PCa, and BCa datasets. Although the exact BAT was not known for either DRO or patient data, we observed better quality of model fit when the estimated BAT was in agreement with the visually observed bolus arrival.
Automatic BAT detection must be accurate, reliable, and reproducible in order to be adopted in clinical practice. We compared four automatic BAT estimation algorithms on a clinical dataset of PCa and BCa DCE-MRI. With the exception of the LL method, which resulted in a low number of valid voxels, the other three methods-PL, OQ, and PG-yielded an acceptable performance but with differences in the percentage of valid voxels. However, due to the small size of TROIs and homogeneity of the uptake across the ROI voxels, the results of the mean of BAT TRF were comparable across the three PL, OQ, and PG methods. However, for the whole prostate gland ROIs, variation in number of valid voxels and mean of BAT TRF was higher than TROIs. For all of the PCa and BCa patients, the results of the OQ method were superior in terms of the number of well-fitted voxels. The finding of poorer fit within the whole gland may be related to the known heterogeneity of perfusion within the entire prostate gland compared to the relative homogeneity within the peripheral zone (where these tumors were located). It has been shown that peak enhancement from baseline significantly differs in glandularductal tissue versus stromal/low ductal tissues. 46 For BCa patients, despite the variations in BAT TRF measurements by different estimators, in all patients there was agreement by all four methods in the direction of K trans percent change in the ROI statistics between the baseline and followup longitudinal DCE-MRI images. There were a small number of valid voxels for visit 2 (after NACT). It is possible that this may be due to overall decrease in vascularity with treatment, decreasing the availability of valid voxels.
In this study, we distinguished BAT TRF from BAT AIF due to their differences in characteristics and contributions to the PK analysis results. Due to the high uptake slope of the AIF curve proximate to the time instance of the CA injection, it is usually less challenging for the automatic methods to detect BAT AIF compared to detection of BAT TRF in which cases in which CA uptake is performed more slowly. However, it should be emphasized that accurate measurement of BAT AIF is critical as it has a direct effect on measurement of PK metrics.
Except for the two segment linear model (LL), the results of the three other automatic BAT estimation methods were comparable to each other. Although the PL method showed good accuracy, it was significantly slower than the other methods due to the large search region for two parameters for each voxel concentration curve. The PG method tended to fall in local maxima, which could lead to overestimation of BAT values. Applying upper threshold for removing the overestimated outliers from the analysis made the ROI averaged results in the same range as the other methods. One strong advantage of the OQ compared to the other methods was the use of AIF prior knowledge in detection of BAT AIF . A practical complication of using the OQ approach is that no open source implementation of this method is available. We used implementation of this method from a commercial prototype software. Although the LL method was not intended for use in TRF, nevertheless, after keeping the valid voxels, it gives comparable results in BCa dataset.
The adopted voxel analysis methodology of keeping only well-fitted curves in the ROI-based PK analysis showed improvements in reproducibility of the PK estimates in the four methods. Voxels with lack of contrast uptake (e.g., necrotic cells) were, after applying the criteria, also filtered out of the analysis. It is, therefore, possible that some voxels were classified as invalid due to poor fits that were caused by issues unrelated to BAT TRF methodology. We recognize that there are a multitude of factors that can affect TM, as investigated by Gill et al. 47 The study had limitations. Only BAT timepoints that were aligned with temporal sampling of the data were used, which will introduce errors as large as AEhalf of the sampling time. Only four automatic methods for estimation of BAT were compared. Indeed, more accurate methods of BAT estimation may lead to more accurately estimated PK parameters. The true value of the BAT was unknown, so there was no gold standard to assess the accuracy of the methods.
There are numerous sources that can lead to inaccuracies in estimating PK parameters. Our goal was to focus on one specific parameter. The point of this manuscript was to quantify inaccuracies resulted from independent incorrect BAT estimation, which is used subsequently to estimate PK parameter. It was not our goal to improve accuracy of PK modeling by attempting to reduce various sources of inaccuracies. Therefore, the other parts of our implementation are intentionally kept fixed and follow the methodology commonly implemented in other tools. In previous works, 13, 43, 48 we have also systematically quantified some of the other important considerations such as the choice of AIF and intrinsic T 1 value of the tissue.
In this study, we did not include the plasma volume fraction term (ν p ) in our PK model. The rationale for using TM without ν p is that the model is widely accepted and used in the community as a practical solution. Both TM and the extended Tofts model (ETM) 7 are standard tools for analysis of DCE-MRI images. A recent article surveying and comparing the DCE MRI quantitative analysis tools used by the participants of the NCI QIN 37 showed that majority of the software tools used implemented the two parameters TM. TM is also the model suggested by the DCE MRI quantification profile developed by the QIBA of the Radiological Society of North America. 49 We believe the considerations above justify the use of the standard TM as the benchmark for evaluating the effect of BAT methods. Since ETM models account for plasma fraction in the voxel, BAT delay correction is likely to have an even bigger impact in ETM models, but this exploration is outside the scope of this study.
In conclusion, we observed that BAT choice and AIF delay correction can significantly affect characterization of tissue microvasculature using TM. Depending on the choice of the BAT technique, the majority of the tumor voxels may be considered invalid or unsuitable for analysis due to either biologically unrealistic BAT value (less than the BAT of the AIF), biologically unrealistic values of the estimated model parameters, or poor fit of the model. In the situations where temporal resolution is large and no significant variation in bolus arrival delay is expected across the ROI, constant BAT can be prescribed manually. However, in the cases where per-voxel estimation of BAT is required, we show that the choice of certain BAT approaches may lead to inability of the TM to characterize the majority of voxels within the region or may not cover the areas of tumor that are of particular interest.
The findings of this study can be used to motivate novel PK analysis and BAT search strategies. As an example, one strategy could be to search over a range of delay corrections to identify the one that improves R 2 and the number of valid voxels. Another approach could be to perform BAT estimation that expects the neighboring voxels to have similar BAT-all of the methods we investigated in this study operate independently on individual voxels.
We expect that this study will contribute to improved reproducibility of DCE MRI analysis by making the researchers aware of the effect of the BAT detection method on the result and motivate future development of robust and improved BAT detection techniques.
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